Sign up to save your podcasts
Or
Share ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial
In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
View all episodes
By American College of Cardiology
3.8
4747 ratings
In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
More shows like ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
View all
JAMA Editors' Summary
130 Listeners
NEJM This Week
319 Listeners
JACC Podcast
160 Listeners
This Week in Cardiology
862 Listeners
JAMA Clinical Reviews
494 Listeners
JACC Specialty Journals
22 Listeners
Circulation on the Run
32 Listeners
JAMA Medical News
87 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
135 Listeners
Core IM | Internal Medicine Podcast
1,082 Listeners
ACC CardiaCast
39 Listeners
Annals On Call Podcast
186 Listeners
Cardionerds: A Cardiology Podcast
415 Listeners
Mayo Clinic Cardiovascular CME
35 Listeners
Sensible Medicine
135 Listeners